Alkermes plc
NASDAQ:ALKSBiotechnology
+$0.79 today
- Market cap
- $7.87B
- Beta
- 0.33
- P/E (TTM)
- 49.1
- EPS (TTM)
- $0.92
Volume 1.39M
Average 2.33M
ALKS Common Stock Issued
Cash raised by issuing new shares.
Alkermes plcNASDAQ: ALKS
Common Stock Issued · Q3 FY2026 · quarter ended Sep 2026
Common stock issued turns negative
Q3 FY2026 common stock issued was -$42.01M, compared with $622K a year earlier. Trailing-twelve-month common stock issued was $11.18M. Over 3 fiscal years it compounded at +30.3% a year.
Context
- Common stock issued amounted to 2.9% of revenue in FY2025, up 1.2 pp from a year earlier.
- Common stock issued increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly common stock issued holds near -$42.01M or moves back toward the trailing-twelve-month quarterly average of $2.79M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 43.41M USD
- Year-over-year change
- +57.4%
- 4-year CAGR
- +14.4%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 43.41M | +57.4% |
| FY2024 | 2024-12-31 | 27.57M | +64.5% |
| FY2023 | 2023-12-31 | 16.76M | -14.6% |
| FY2022 | 2022-12-31 | 19.63M | -22.5% |
| FY2021 | 2021-12-31 | 25.32M | — |
Common Stock Issued vs competitors
How ALKS compares with its peers on the latest reported figures
- ALKS's LTM Sep 2026 common stock issued of $11.18M is the 6th largest of the 7 companies compared; the peer median is $68.12M.
- Its year-over-year change of -72.4% is the lowest of 6, against a peer median of +154.8%.
- Common stock issued amounts to 0.6% of revenue for ALKS, versus a peer median of 4.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $171M | +67.5% | +42.5% | 4.6% | |
| LTM Jun 2026 | $117.67M | +26.6% | -19.7% | 15.2% | |
| LTM Sep 2026 | $85.19M | +167.3% | — | 1.8% | |
| LTM Jun 2026 | $51.05M | +154.8% | +82.6% | 4.5% | |
| LTM Jun 2026 | $50.09M | +219.9% | +44.7% | 6.0% | |
| LTM Sep 2026 | $11.18M | -72.4% | +30.3% | 0.6% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ALKS) | $68.12M | +154.8% | +43.6% | 4.6% | |
Competitors are the stored peer set for ALKS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (48.17M) | (158.27M) | 355.76M | 367.07M | 241.66M |
| Depreciation & Amortization | 78.65M | 77.86M | 74.93M | 28.53M | 27.17M |
| Deferred Income Tax | 5.08M | (32.8M) | (99.9M) | 40.52M | 28.77M |
| Stock-Based Compensation | 87.62M | 94.25M | 100.91M | 96.64M | 98.72M |
| Change in Working Capital | (25.55M) | 12.71M | (36.66M) | (98.15M) | 119.12M |
| Accounts Receivables | (38.01M) | 25.25M | (44.51M) | (56.34M) | 55.49M |
| Inventory | (24.77M) | (31.02M) | (2.71M) | 3.09M | (14.06M) |
| Accounts Payables | 43.31M | 15.53M | 23.01M | (57.97M) | 100.89M |
| Other Working Capital | (6.08M) | 2.95M | (12.45M) | 13.06M | (23.2M) |
| Other Non-Cash Items | 4.08M | 27.28M | 6.33M | 4.51M | 5.31M |
| Operating Cash Flow | 101.72M | 21.04M | 401.35M | 439.12M | 520.75M |
| Capital Expenditures | (29.02M) | (38.26M) | (48.05M) | (33.48M) | (40.42M) |
| Acquisitions (Net) | (713K) | 485K | 0 | 97.98M | 2.79M |
| Purchases of Investments | (340.42M) | (309.67M) | (254.47M) | (486.55M) | (364.37M) |
| Sales of Investments | 295.01M | 281.63M | 355.52M | 310.29M | 697.49M |
| Other Investing Activities | 8.94M | 1.27M | 354K | 461K | 0 |
| Investing Cash Flow | (66.2M) | (64.54M) | 53.36M | (111.31M) | 295.5M |
| Debt Repayment | 20.32M | (3M) | (3M) | (291.79M) | 0 |
| Common Stock Issued | 25.32M | 19.63M | 16.76M | 27.57M | 43.41M |
| Common Stock Repurchased | (16.57M) | (18.2M) | (28.47M) | (200.28M) | (31.03M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (275M) | (29.64M) | 0 |
| Financing Cash Flow | 29.07M | (1.57M) | (289.71M) | (494.14M) | 12.38M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 64.58M | (45.07M) | 165M | (166.32M) | 828.63M |
| Free Cash Flow | 72.7M | (17.21M) | 353.31M | 405.64M | 480.33M |
Alkermes plc
NASDAQ:ALKS
Intrinsic Alpha fair value
Locked
Current Price
$46.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.